Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2020 - Issue 1

The Vascular Endothelial Growth Factor-A Gene Polymorphism Predicts Clinical Outcomes Among Acute St-Segment Elevation Myocardial Infarction Patient Download PDF


Inna M. Kutia, Mykola P. Kopytsya, Yaroslava V. Hilova, Olga V Petyunina, Alexander E. Berezin
Abstract

Context: Vascular endothelial growth factor (VEGF) is an angiopoetic factor, the variability of circulating level of which is mediated by expression of specific VEGF-A gene variants. Aims: To investigate the predictive role of VEGF-A gene polymorphism for clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients. Settings and Design: An open prospective single-center cohort study. Methods and Material: 135 patients with acute STEMI and 30 healthy volunteers were enrolled in the study. The G634C polymorphism in the VEGF-A gene was performed by real-time polymerase chain reaction at baseline. The 6-month combined clinical endpoint was determined. Statistical analysis used: The univariate and multiple variate log-regression analysis. Results: The entire patient population was distributed into two groups depending on G634G-genotype (n = 70) and combination with G634C and C634C-genotypes (n=65). Unadjusted multivariate regressive logistic analysis has shown peak troponin I at admission, Killip class of heart failure > 2, GC/CC polymorphisms in VEGF-A gene, dynamic increased NT-proBNP and VEGF-A levels for 6 months, and remained independent predictors for the combined endpoint. After adjustment for dynamic changes of NT-proBNP and VEGF-A levels, the GC/CC polymorphisms in the VEGF-A gene remained an independent predictor of clinical outcome. Kaplan-Meier curves have demonstrated that GG VEGF-A genotype was associated with a lower frequency of combined endpoint when compared with GC/CC VEGF-A genotypes (Log-rank p = 0.02). Conclusions: The G634C polymorphism in the VEGF-A gene was found as an independent predictor for 6-month combined endpoints amid STEMI patients‎.

Cite this article

QR code:

Short Link:
Quick Access

Pharmacophore
ISSN: 2229-5402


Pharmacophore
© 2022 All rights reserved